Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer

Over the course of the past three decades, human epidermal growth factor receptor 2 (HER2)–targeted treatment has dramatically transformed outcomes for patients with HER2-positive breast cancer across both early- and late-stage disease. HER2 has also emerged as a clinically meaningful biomarker in several tumor types, with HER2-targeted therapies showing substantial… Over the course of the past three decades, human epidermal growth factor receptor 2 (HER2)–targeted treatment has dramatically transformed outcomes for patients with HER2-positive breast cancer across both early- and late-stage disease. HER2 has also emerged as a clinically meaningful biomarker in several tumor types, with HER2-targeted therapies showing substantial…